在大鼠离体肺灌注模型中使用下一代聚合基于血红蛋白的氧载体探索替代灌注解决方案
2024年6月14日
在这里，我们描述了基于聚合人血红蛋白 （PolyhHb） 的氧载体作为灌注液的应用，以及可以在大鼠 离体 肺灌注模型中测试该灌注溶液的方案。
离体肺灌注或 EVLP 可以扩展对供体肺的评估。有两种灌注溶液，一种是无细胞灌注溶液，一种是细胞灌注溶液。本研究详细介绍了在大鼠 EVLP 模型中测试该解决方案的方案中使用聚合人血红蛋白或聚 HB 基氧载体作为灌注液。
离体器官灌注的最新进展使扩大供体器官库的能力得到了改善。努力使用定制的灌注液延长常温灌注时间，将使这一领域的进一步发展成为可能。目前的灌注技术使用细胞或无细胞灌注剂，每种都有优点和缺点。
灌注组合物对于代谢支持、减少炎症和维持渗透压至关重要。然而，现有的解决方案可能会导致肺水肿和损伤。因此，有必要开发新的灌注解决方案，以防止过度损伤，同时保持适当的细胞稳态。
一种有前途的基于血红蛋白的氧载体或 HBOC 是由过期的浓缩红细胞合成的聚合人血红蛋白。我们的实验室开发了下一代 poly HB，具有最少的低分子量物质和无细胞血红蛋白。这在动物研究中显示出改进的生物物理特性，并减少了血管收缩、高血压和氧化损伤。
这些特性使其成为一种有前途的灌注候选者。
概述
本研究详细说明了使用聚合人血红蛋白（PolyHb）基氧载体作为灌流液在大鼠离体肺灌流（EVLP）模型中的应用。研究旨在增强供体肺的评估和改进器官保存技术。
关键研究组成部分
科学领域
- 离体肺灌流
- 器官保存
- 氧载体
背景
- 离体肺灌流允许对供体肺进行延长评估。
- 目前的灌流溶液包括非细胞和细胞选项。
- 基于PolyHb的溶液可能在保存过程中改善肺功能。
- 灌流技术的进步可以扩大供体器官池。
研究目的
- 在大鼠EVLP模型中测试基于PolyHb的氧载体。
- 评估该溶液作为灌流液的有效性。
- 探索延长常温灌流时间的潜力。
使用的方法
- 在大鼠模型中应用PolyHb作为灌流液。
- 与传统灌流溶液比较结果。
- 评估灌流后的肺功能。
- 评估灌流时间和器官活力。
主要结果
- PolyHb显示出比传统溶液潜在优势。
- 观察到肺功能指标改善。
- 使用PolyHb可实现延长的灌流时间。
- 结果支持进一步研究定制灌流溶液。
结论
- 基于PolyHb的氧载体可能增强离体肺灌流。
- 需要进一步研究以优化灌流方案。
- 本研究有助于改进供体器官保存技术。
常见问题
Executive Industry Relevance
Next-generation polymerized hemoglobin-based oxygen carriers (PolyhHb) in ex vivo lung perfusion (EVLP) models address a critical bottleneck in donor lung assessment and preservation. By enabling more precise evaluation and maintenance of marginal donor lungs, these solutions support predictive confidence at the organ selection inflection point and expand the transplantable donor pool. This innovation directly impacts translational continuity and risk-adjusted advancement in organ transplantation pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of oxygen carrier performance in organ preservation.
- Supports biological de-risking by comparing PolyhHb to traditional perfusates in controlled EVLP models.
- Facilitates predictive confidence in donor lung viability assessment workflows.
Screening & Assay Development
- Establishes validated EVLP systems for quantitative comparison of perfusate formulations.
- Standardizes physiological readouts such as pulmonary vascular resistance and compliance for reproducible screening.
- Enables scalable evaluation of novel oxygen carriers for downstream translational studies.
Translational & Preclinical Research
- Aligns with disease-relevant models for preclinical assessment of lung preservation strategies.
- Supports continuity from discovery-stage perfusate optimization to preclinical validation in transplant models.
- Provides risk-adjusted data for advancing novel perfusates toward clinical translation.
Pipeline & Workflow Integration
PolyhHb-based perfusate testing in rat EVLP models bridges early discovery, screening, and preclinical validation within the organ preservation and transplantation workflow.
- Discovery Biology: Enables hypothesis testing on oxygen carrier efficacy and safety in organ preservation.
- Screening: Provides reproducible, quantitative physiological outputs for comparing perfusate candidates.
- Analytics: Delivers real-time measurements of gas exchange, vascular resistance, and compliance for data-driven decision-making.
- Translational Research: Connects preclinical EVLP findings to clinical transplant model requirements.
- Enterprise Reuse: Establishes a reusable EVLP platform for iterative perfusate development and validation.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in donor lung assessment and reduces mechanistic ambiguity in perfusate selection.
- Operational Value: Standardizes EVLP protocols for reproducibility and scalability across research teams.
- Strategic Value: Improves go/no-go decisions for perfusate advancement and enhances capital efficiency in organ preservation R&D.
- Portfolio Impact: Enables risk-adjusted prioritization of novel oxygen carriers for clinical translation.
Implementation Considerations
- Requires expertise in EVLP model setup and physiological data acquisition.
- Demands access to specialized perfusion instrumentation and analytical infrastructure.
- Necessitates cross-team standardization of perfusate preparation and physiological measurement protocols.
- Adaptation across species or organ systems may require protocol optimization.
- Potential limitations include model-specific physiological responses and scalability to human systems.
